USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
The Ethiopian government is offering tax and loan incentives to encourage local pharmaceutical production in a bid to reduce drug costs, boost jobs, improve economic growth and enhance foreign exchange inflow. 6 April 2016
UK specialty drugmaker Martindale Pharma has signed a new distribution agreement with Saudi Arabian partner Musaed El Seif Saudi Pharmaceutical Co as part of its new international expansion strategy. 4 April 2016
Swiss pharma giant Novartis has published updated 2015 segment financials taking into account the company's major restructuring which was announced in January. 1 April 2016
Irish company Fastnet Equity, which last year announced a switch of focus from oil exploration to pharmaceuticals, is seeking to complete a £29.6 million takeover of orphan drug development firm Amryt Pharmaceuticals. 31 March 2016
Japanese ophthalmology specialist Santen Pharmaceutical and state-owned Chinese group Chongqing Kerui have joined forces in a partnership promised to provide people in China with affordable ophthalmic products. 23 March 2016
German biotech firm Evotec has announced that it has set up a new spin-out company in the field of nanoparticle-based therapeutics for immunological disorders. 22 March 2016
Shield Therapeutics has raised £32.5 million ($47 million) in a UK flotation ahead of its proposed admission to the Alternative Investment Market (AIM) branch of the London Stock Exchange (LSE). 12 February 2016
In our weekly expert view piece, John Maloney, commerical product director at Bloomberg BNA and editors of Bloomberg Law: corporate transactions, examines the proposed Shire-Baxalta merger. 9 February 2016
Oxis International has said following debt restructuring the company will be in sound financial shape to continue its Phase I/ II clinical trial of OXS-1550, a drug to treat non-Hodgkins lymphoma and leukemia. 2 February 2016
Medicxi Ventures on Tuesday announced the close of Medicxi Ventures 1 (MV1), a new 210 million euro ($250 million) fund that will focus on early-stage life sciences investments. 2 February 2016
In our weekly expert view piece, Joe Stelzer, managing partner at Cavendish Corporate Finance LLP, examines the emerging ‘research by acquisition’ model in big pharma. 2 February 2016
Dutch biopharmaceutical company Kiadis Pharma has signed a deal with The Leukemia and Lymphoma Society (LLS) to further develop its lead product ATIR10, it has been announced. 1 February 2016
Germany’s Merck on Wednesday announced two appointments to head its businesses in North America and China in a bid to strengthen its position in the regions. 27 January 2016
Korean biopharmaceutical company Celltrion is to start using cloud-based technology to accelerate development of its biosimilars programs in rheumatoid arthritis, respiratory diseases and cancer. 22 January 2016
Clinical-stage gene delivery company GenVec said there is no certainty the trials for its lead product CGF166 to treat hearing loss will continue. 21 January 2016
US health care giant Johnson & Johnson has said it will cut about 3,000 jobs in its medical-devices unit in a bid to revive the struggling business. 20 January 2016
Pharma giant Pfizer said it is pouring in a total of $46 million into four early-stage research companies in a bid to expand its R&D investments. 11 January 2016
Switzerland-based Cardiorentis AG said it has raised 60 million Swiss Franc ($60 million) via private investors to advance its Phase III trials for Ularitide, a therapy for acute decompensated heart failure (ADHF), including upcoming regulatory submissions expected in the second half of 2016. 11 January 2016
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news